Resources from the same session
LBA61 - HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: A multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC)
Presenter: Liwei Wang
Session: Mini Oral session: GI, upper digestive
Resources:
Abstract
Slides
Webcast
1296MO - PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC)
Presenter: Michel Ducreux
Session: Mini Oral session: GI, upper digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA61 and 1296MO
Presenter: Teresa Macarulla Mercade
Session: Mini Oral session: GI, upper digestive
Resources:
Slides
Webcast
52MO - A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC)
Presenter: Arndt Vogel
Session: Mini Oral session: GI, upper digestive
Resources:
Abstract
Slides
Webcast
53MO - Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116)
Presenter: Arndt Vogel
Session: Mini Oral session: GI, upper digestive
Resources:
Abstract
Slides
Webcast
54MO - Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial
Presenter: Angela Lamarca
Session: Mini Oral session: GI, upper digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant 52MO, 53MO, 54MO
Presenter: Maeve Lowery
Session: Mini Oral session: GI, upper digestive
Resources:
Slides
Webcast
1204MO - PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
Presenter: David Tougeron
Session: Mini Oral session: GI, upper digestive
Resources:
Abstract
Slides
Webcast
1205MO - Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen
Presenter: Geoffrey Ku
Session: Mini Oral session: GI, upper digestive
Resources:
Abstract
Slides
Webcast